Syros Pharmaceuticals, Inc. Overview
Pro stress-test →Syros Pharmaceuticals is a biopharmaceutical company focused on the development of treatment for hematologic malignancies. The company operates within the biopharmaceutical sector, focusing on the development of treatments that control the expression of genes to address the root causes of diseases, leveraging its proprietary gene control platform to design therapies for cancer and monogenic diseases.
Strategic Profile
Pro stress-test →Lead product candidates include Tamibarotene, a selective retinoic acid receptor alpha agonist in Phase III clinical trial for myelodysplastic syndrome and Phase II for acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor in Phase I clinical trial. The company is navigating significant development challenges following recent clinical trial setbacks.
Competitive Landscape
Pro stress-test →Syros competes in the hematologic malignancy and gene control therapeutic space against large pharma and other biotech companies. The company's gene control platform represents a differentiated approach, but recent clinical failures have undermined competitive positioning. Key competitors include larger oncology-focused pharmaceutical companies with more established development pipelines and financial resources.
Industry Context
Syros Pharmaceuticals, Inc. operates in Biopharmaceutical - Hematologic Malignancies & Gene Control Therapeutics.
Key facts
Founded: 2011 · Headquarters: Cambridge, Massachusetts · Revenue: $0.39M · Market cap: $0.68M